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progressive, and fatal neurodegenerative disease character-
ized by variable loss of upper and lower motor neurons (1). 
Biomarkers that are sensitive to the progression of disease 
have the potential to shorten therapeutic trials and provide 
new drug targets. Study of the metabolome offers the po-
tential to identify disease-specific patterns for ALS, possibly 
providing such biomarkers and new insights into the de-
ranged biochemical pathways associated with ALS. Metabo-
lomic studies in blood and cerebrospinal fluid (CSF) have 
been performed utilizing proton nuclear magnetic reso-
nance spectrometry (2–4), GC/MS, and LC/MS (5, 6). Sig-
nificant differences between patients and controls have 
been observed, consistent with a range of pathogenic 
mechanisms  that have been described  in ALS,  including 
mitochondrial dysfunction, oxidative stress, excitotoxicity, 
neuroinflammation, and hypermetabolism (7).
Abstract As neurons die, cholesterol is released in the cen-
tral nervous system (CNS); hence, this sterol and its metab-
olites may represent a biomarker of neurodegeneration, 
including in amyotrophic lateral sclerosis (ALS), in which 
altered cholesterol levels have been linked to prognosis. 
More than 40 different sterols were quantified in serum and 
cerebrospinal fluid (CSF) from ALS patients and healthy 
controls. In CSF, the concentration of cholesterol was found 
to be elevated in ALS samples. When CSF metabolite levels 
were normalized to cholesterol, the cholesterol metabolite 
3,7-dihydroxycholest-5-en-26-oic acid, along with its pre-
cursor 3-hydroxycholest-5-en-26-oic acid and product 7-
hydroxy-3-oxocholest-4-en-26-oic acid, were reduced in 
concentration, whereas metabolites known to be imported 
from the circulation into the CNS were not found to differ 
in concentration between groups. Analysis of serum re-
vealed that (25R)26-hydroxycholesterol, the immediate pre-
cursor of 3-hydroxycholest-5-en-26-oic acid, was reduced 
in concentration in ALS patients compared with controls.  
We conclude that the acidic branch of bile acid biosynthesis, 
known to be operative in-part in the brain, is defective in 
ALS, leading to a failure of the CNS to remove excess cho-
lesterol, which may be toxic to neuronal cells, compounded 
by a reduction in neuroprotective 3,7-dihydroxycholest-
5-en-26-oic acid.—Abdel-Khalik, J., E. Yutuc, P. J. Crick, J-Å. 
Gustafsson, M. Warner, G. Roman, K. Talbot, E. Gray, W. J. 
Griffiths, M. R. Turner, and Y. Wang. Defective cholesterol 
metabolism in amyotrophic lateral sclerosis. J. Lipid Res. 
2017. 58: 267–278.
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20 ng of 7-[25,26,26,26,27,27,27-2H7]hydroxycholesterol (7-




2H7]HCO),  and  20  µg  of 
[25,26,26,26,27,27,27-2H7]cholesterol (deuterated sterols from 
Avanti Polar Lipids Inc., Alabaster, AL) with sonication in an ul-
trasonic bath. After 5 min, 350 µl of water was added to make the 
solution 70% ethanol. After a further 5 min of sonication, the so-
lution was centrifuged at 17,000 g at 4°C for 30 min.
To separate cholesterol from the more polar oxysterols and ste-
roid acids, the sample solution, now in 1.5 ml of 70% ethanol, was 
loaded onto a 200-mg Certified Sep-Pak C18  column  (Waters,  
Elstree, Herts, U.K.) preconditioned with 4 ml of absolute etha-
nol and 6 ml of 70% ethanol. The solvent flow rate through the 




oxysterols, cholestenoic, and cholenoic acids elute. A second frac-
tion (SPE1-Fr2) was  collected by eluting with a  further 4 ml of 
70% ethanol, before fraction 3 containing cholesterol and sterols 
of similar hydrophobicity was eluted with 2 ml of absolute ethanol 
(SPE1-Fr3). Finally, a fourth fraction eluting in 2 ml of absolute 
ethanol was collected, containing lipid more hydrophobic than 
cholesterol (SPE1-Fr4). Each fraction was divided into two equal 
subfractions,  (A)  and  (B),  and  allowed  to  dry  overnight  under 
vacuum. Note that a hydrolysis step was not included in the sam-
ple preparation procedure, and by removing cholesterol from its 
metabolites  in  the first  step  of  sample preparation,  subsequent 









cholesterol oxidase. One hundred fifty microliters of glacial acetic 
acid was added  to  subfractions (A) and (B) and vortexed. One 





ing, the derivatization reaction was left to proceed at room tem-
perature, overnight in the dark.
To remove excess derivatization reagent, a 60-mg Oasis HLB 
(Waters) column was conditioned with 6 ml of 100% methanol,  
6 ml of  10% methanol,  and 4 ml of  70% methanol before  the 
samples (3,250 µl, 70% organic) were loaded. The sample vessel 
was washed with 1 ml of 70% methanol, and the wash was applied 
to the column. One milliliter of 35% methanol was used to rinse 
the column, and the combined 5 ml of effluent was diluted with 
4 ml of water to give 9 ml of 35% methanol solution. This solution 




recycling procedure by which sterols, oxysterols, cholestenoic, 
and cholenoic acids were extracted by the column, whereas de-
rivatization reagents eluted to waste. Six milliliters of 10% metha-
nol was added to wash the column. Finally, 25-D3, oxysterols, 




Cholesterol, both the nonesterified molecule and its esters 
with fatty acids, represents a major component of the total 
lipid content of cells in vertebrates. On a number of fronts, 
cholesterol and its metabolites represent potential bio-
markers  for ALS. High plasma  levels  of  cholesterol  have 
been suggested  to be neuroprotective  for ALS and  to be 
associated with an increased survival time (9–11), but other 
data suggest that accumulation of cholesterol esters and 




part of the bile acid biosynthesis pathway, was recently 
identified as a susceptibility gene for sporadic ALS (13). In 




cholesterol is released from cells. Cholesterol and its me-
tabolites in the CNS are predominantly in a nonesterified 
form (15), and it the nonesterified molecules that are re-
sponsible  for  regulating cholesterol homeostasis  (16, 17) 
and are  the  ligands  to nuclear  receptors  (18,  19)  and  li-
gands to G-protein-coupled receptors (20, 21). We aimed 
to characterize and quantify nonesterified cholesterol and 
the widest range of nonesterified metabolites in CSF and 
serum from ALS patients compared with a group of healthy 
controls (see Table 1 for molecules analyzed). An LC/MS 
approach was adopted to exploit charge-tagging to ensure 
maximum sensitivity and to gain structural information al-















criteria. All participants provided informed consent, and the study 
was approved by the South Central Oxford Ethics Committee B. Ad-
ditional control CSF samples for method development were from a 
study performed at Methodist Hospital, Houston, TX.
Methods
Serum. One hundred microliters of serum was added drop-
wise to a solution of 1,050 µl of absolute ethanol containing 2 ng 
of  25-[26,26,26,27,27,27-2H6]hydroxyvitamin D3 (25-[
2H6]D3, 
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Cholesta-5,7-dien-3-ol (7-dehydrocholesterol) + cholesta-5,8-dien-3-olb 7-DHC + 8-DHC LMST01010069 /NA Yes
Cholesta-5,24-dien-3-ol (desmosterol) 24-DHC LMST01010016 Yes
Cholest-5-en-3-ol (cholesterol) C LMST01010001 Yes
Cholesta-5,8-diene-3,24(or 25)-diol 24(or 25)H-8DHC NA No
Cholesta-5,8-diene-3,26-diol 26H-8-DHC NA No
3-Hydroxycholest-5-en-7,8-epoxide 7,8-EC NA Yes
9,10-Secocholesta-5Z,7E,10-triene-3S,25-diol (25-Hydroxyvitamin D3) 25-D3 LMST03020246 Yes
9,10-Secocholesta-5Z,7E,10-triene-3S,24,25-triol (24,25-Dihydroxyvitamin D3) 24,25-D3 LMST03020273 or LMST03020274 Yes
Cholest-4(or 5)-ene-3,6-diol (6-hydroxycholesterol)c 6-HC NA Yes
Cholest-5-ene-3,7-diol (7-hydroxycholesterol) 7-HC LMST01010013 Yes
7-Hydroxycholest-4-en-3-one 7-HCO LMST01010271 Yes
Cholest-5-ene-3,7-diol (7-hydroxycholesterol) 7-HC LMST01010047 Yes
3-Hydroxycholest-5-en-7-one (7-oxocholesterol) 7O-C LMST01010049 Yes
3-Hydroxycholest-5-en-24-one (24-oxocholesterol) 24O-C LMST01010133 Yes
Cholest-5-ene-3,24S-diol (24S-hydroxycholesterol) 24S-HC LMST01010019 Yes
Cholest-5-ene-3,25-diol (25-hydroxycholesterol) 25-HC LMST01010018 Yes
Cholest-5-ene-3,(25R)26-diol (27-hydroxycholesterol) 26-HC LMST01010057 Yes
Cholest-5-ene-3,12-diol (12-hydroxycholesterol)d 12-HC NA No
Cholest-5-ene-3,7,12-triol (7,12-dihydroxycholesterol)d 7,12-diHC LMST04030165 No
7,12-Dihydroxycholest-4-en-3-oned 7,12-diHCO LMST04030114 No
Cholest-5-ene-3,7,25-triol (7,25-dihydroxycholesterol) 7,25-diHC LMST04030166 Yes
7,25-Dihydroxycholest-4-en-3-one 7,25-diHCO LMST04030107 Yes
Cholest-5-ene-3,7,26-triol (7,26-dihydroxycholesterol) 7,26-diHC LMST04030081 Yes
7,26-Dihydroxycholest-4-en-3-one 7,26-diHCO LMST04030157 Yes
3,22-Dihydroxycholest-5-en-24-oned 22-HC-24-O NA No
3,5-Dihydroxycholest-7-en-6-one (dihydrocholestenone) LMST01010260 Yes
Cholesta-5-en-3,24,25-triol (24,25-dihydroxycholesterol) 24,25-diHC NA Yes
3-Hydroxycholest-5-en-26-oic acid 3-HCA LMST04030072 Yes
3-Oxocholest-4-en-26-oic acid 3O-CA NA Yes
3-Hydroxycholesta-5,7-dien-26-oic acide 3H-7-DHCA NA Yes
3-Oxocholesta-4,6-dien-26-oic acidf 3O-6-DHCA NA Yes
3,7-Dihydroxycholest-5-en-26-oic acide 3,7-diHCA LMST04030148 Yes
7-Hydroxy-3-oxocholest-4-en-26-oic acidf 7H,3O-CA LMST04030149 Yes
Total 3,7-Dihydroxycholest-5-en-26-oic acidg 3,7-diHCA LMST04030148 Yes
Total 7-Hydroxy-3-oxocholest-4-en-26-oic acidh 7H,3O-CA LMST04030149 Yes
3,7-Dihydroxycholest-5-en-26-oic acid 3,7-diHCA NA Yes
3-Hydroxy-7-oxocholest-5-en-26-oic acid 3H,7O-CA LMST04030215 Yes
3,22,25-Trihydroxycholest-5-en-24-oned 22,25-diHC-24-O NA No
7,x,y-Trihydroxycholest-4-en-3-oned 7,x,y-triHCO NA No
7,24(or26),25-Trihydroxycholest-4-en-3-oned 7,24(or 26),25-triHCO NA No
3,7,24-Trihydroxycholest-5-en-26-oic acid 3,7,24-triHCA NA Yes
7,24-Dihydroxy-3-oxocholest-4-en-26-oic acid 7,24-diH,3O-CA NA Yes
3,7,24-Trihydroxycholest-5-en-26-oic acii 3,7,24-triHCA NA No
7,24-Dihydroxy-3-oxocholest-4-en-26-oic acii 7,24-diH,3O-CA NA No
3,7,25-Trihydroxycholest-5-en-26-oic acid 3,7,25-triHCA NA Yes
7,25-Dihydroxy-3-oxocholest-4-en-26-oic acid 7,25-diH,3O-CA NA Yes
3,7,25-Trihydroxycholest-5-en-26-oic acii 3,7,25-triHCA NA No
7,25-Dihydroxy-3-oxocholest-4-en-26-oic acidi 7,25-diH,3O-CA NA No
7,x-Dihydroxy-3-oxocholest-4-en-26-oic acidd 7,x-diH,3O-CA NA No
3,7,12-Trihydroxycholest-5-en-26-oic acidd 3,7,12-triHCA NA No
7,12-Dihydroxy-3-oxocholest-4-en-26-oic acidd 7,12-diH,3O-CA LMST04030150 No
Trihydroxy-3-oxocholest-4-en-26-oic acid NA No
7-Hydroxy-3,24-bisoxocholest-4-en-26-oic acidd 7H,3,24-diO-CA NA No
7-Hydroxy-26-nor-cholest-4-ene-3,24-dioned 7H,26-nor-C-3,24-diO NA No
3,7-Dihydroxychol-5-en-24-oic acid 3,7-5-BA LMST04010217 Yes
7-Hydroxy-3-oxochol-4-en-24-oic acid 7H,3O-4-BA LMST04010239 Yes




c Dehydration product of cholestane-3,5,6-triol.
d Authentic standard not available; annotation based on retention time, exact mass, and MS3 fragmentation.
e The 3,7-diHCA dehydrates to 3H-7-DHCA.
f The 7H,3O-CA dehydrates to 3O-6-DHCA.
g Sum of intact 3,7-diHCA and its dehydration product 3H-7-DHCA.
h Sum of intact 7H,3O-CA and its dehydration product 3O-6-DHCA.
i Identification based on comparison to 7-isomer.
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three to five scan events were performed: one high-resolution 
(120,000, full-width at half maximum height at m/z 400) MS scan 
event in the Orbitrap analyzer in parallel with two to four multi-
stage fragmentation (MSn)  scan  events  in  the  LTQ  linear  ion 
trap. Quantification was performed by stable isotope dilution or 






2H6]D3,  and  0.8  µg of  [
2H7]cholesterol 
with sonication in an ultrasonic bath. Six hundred fifty microliters 
of water was added, and the solution was sonicated for 5 min, fol-
lowed by centrifugation at 2,400 g at 4°C for 30 min.
The CSF sample solution  in 3 ml of 70% ethanol was  loaded 
onto a 200-mg Certified Sep-Pak C18 column as in the serum proto-
col. However, the 3-ml flow-through was combined with a column 
wash of only 4 ml of 70% ethanol to give SPE1-Fr1 (7 ml) in which 
25-D3,  oxysterols,  cholestenoic,  and  cholenoic  acids  elute. The 
were eluted from the column with 3 × 1 ml 100% methanol (SPE2-
Fr1,2,3) and 1 ml of absolute ethanol (SPE2-Fr4). Oxysterols, 25-
D3, cholestenoic, and cholenoic acids elute in the first 2 ml from 
the column (SPE2-Fr1,2). Cholesterol and sterols of similar polar-
ity elute over 3 ml of methanol (SPE2-Fr1,2,3).
For 25-D3, oxysterol, cholestenoic, and cholenoic acid analysis, 
just  before  analysis  by  LC/MS,  an  equal  aliquot  of  SPE2-Fr1,2 
from  subfractions  (A)  and  (B)  was  combined  together  in  one 
tube.  For  cholesterol  analysis  equal  volumes  of  SPE2-Fr1,2,3 
from subfractions (A) and (B) were combined. In both cases  the  
combined effluent in methanol was diluted with water to achieve 
a concentration of 60% methanol, i.e., the initial composition of 
the mobile phases during LC analyses.
LC/MS and LC/MSn analysis. Analysis was performed on a 
LTQ-Orbitrap  Elite  (Thermo  Fisher  Scientific,  Hemel  Hemp-
stead, UK) equipped with an electrospray probe, and a Dionex 
Ultimate 3000 LC system (Dionex; now Thermo Fisher Scientific), 
essentially  as described previously  (22, 23). For each  injection, 




extend to the most extreme data points, which are no more than 1.5 times the range between first and third 
quartile distant from the box. Points beyond that are plotted individually. Data for other sterols can be found 
in supplemental Table S1. Univariate t tests were performed against the control group. * P < 0.05; ** P < 0.01.
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the upper motor neuron-only, very slowly progressive vari-
ant of ALS, termed PLS (2 male, 4 female, mean age 69), 
were separately compared with the control group. Concen-




out, so all concentrations are for nonesterified com-
pounds). We failed to find any sexual dimorphism in the 
control sample set and thus included both sexes in the cur-
rent study.
There  was  no  significant  difference  in  the  concentra-
tions of cholesterol or its precursors desmosterol (24-DHC) 
or  7-dehydrocholesterol  (7-DHC)  between  ALS,  PLS,  or 
remainder of the sample preparation procedure, including de-
rivatization, was identical to that used for serum, with the exception 
that the final eluates from SPE2 were lyophilized and reconstituted 
in 60% methanol prior to sample injection on the LC system.
Statistics
An ANOVA was run for each sterol. Univariate t tests were per-
formed against the control group: *P < 0.05; **P < 0.01. Concen-
trations given in the text are means ± SDs.
RESULTS
Analysis of sterols, oxysterols, and cholestenoic and 
cholenoic acids in serum




the arrow. Enzymes catalyzing the indicated reactions are shown where known. Univariate t tests were performed against the control group. 
* P < 0.05; ** P < 0.01.
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Fig. 3. Pathway of cholesterol metabolism initiated by the enzymes CYP7A1 and CYP27A1. Changes in ste-
rols concentration  in CSF and serum are  indicated by blue and red arrows,  respectively. The direction of 
change corresponds to the direction of the arrow. Enzymes catalyzing the indicated reactions are shown 
where known. Enzyme abbreviations used are as follows: ACOX2, acyl-CoA oxidase 2, branched chain; AM-
ACR, -methylacyl-CoA racemase; BACS, bile acyl-CoA synthetase; DBP, D-bifunctional protein or multifunc-
tional enzyme type 2 (HSD17B4); SCPx, sterol carrier protein x; VLCS, very long chain acyl-CoA synthetase. 
Univariate t tests were performed against the control group. * P < 0.05; ** P < 0.01.
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concentrations of both desmosterol (P < 0.05) and choles-
terol (P < 0.01) were found to be elevated in CSF from ALS 
patients (Fig. 4, supplemental Table S3). Because ALS is a 
neurodegenerative disease, we speculated that, when cho-
lesterol is released by neurons as they die, it would be me-
tabolized by CYP46A1 to 24S-hydroxycholesterol (24S-HC) 
and by CYP27A1 to members of the acidic pathway of bile 
acid biosynthesis (Figs. 2 and 3, respectively) (25). Surpris-
ingly, when normalized to cholesterol, 24S-HC concentra-
tion was found to be reduced (P < 0.01) in CSF, as were 
members of the acidic pathway of bile acid biosynthesis 
(supplemental Table S4).  Intriguingly,  concentrations of 
7-HC, 7-HCO, 7-HC, and 7O-C, which originate from 
the CYP7A1-initiated arm of the bile acid biosynthesis 
pathway and enter the CSF from the circulation, did not 
differ between ALS patients and controls (Fig. 5). This can 





metabolite 25-hydroxyvitamin D3 (25-D3)  in serum of the 
ALS patients compared with controls (Fig. 1).
The first steps of all cholesterol metabolism lead to hy-
droxycholesterol isomers, collectively known as oxysterols. 
A minor pathway, initiated in activated macrophages, leads 
to 25-hydroxycholesterol (25-HC), followed by subsequent 
metabolism to 7,25-dihydroxycholesterol (7,25-diHC) 
and 7,25-dihydroxycholest-4-en-3-one (7,25-diHCO, Fig. 
2). Of these metabolites, 7,25-diHCO was elevated in ALS 
serum (P < 0.01). 7-Hydroxycholesterol (7-HC) and 7-
hydroxycholest-4-en-3-one (7-HCO)  are  the  first  mem-
bers of the neutral pathway of bile acid biosynthesis (Fig. 3) 
(25);  however,  neither  oxysterol  showed  a  difference  in 
concentration between ALS, PLS, or control samples, and 
nor did 7-hydroxycholesterol (7-HC)  or  7-oxocholes-
terol (7O-C). 7O-C, 7-HC, and 7-HC can be formed via 
free radical oxidation of cholesterol, and these metabolites 
have been suggested as markers of oxidant stress (26).
Conversely,  (25R)26-hydroxycholesterol  (26-HC),  the 
first member of the extrahepatic part of the acidic path-
way  of  bile  acid  biosynthesis,  was  decreased  in ALS  and 
PLS serum compared with controls (P < 0.01), as was 3-





terminal carbon of the cholesterol side chain introducing 
25R stereochemistry results in (25R)26-hydroxycholesterol 
(28). Unless stated otherwise, R stereochemistry is generally 
assumed  at  C-25.  The  nonsystematic  name  for  26-HC, 
widely used in the literature on account of the nomencla-
ture of its synthesizing enzyme, CYP27A1, is 27-hydroxy-
cholesterol.  Levels  of  26-HC  in  the  circulation  are  often 
correlated to cholesterol, with high cholesterol levels asso-
ciated with high levels of 26-HC (29). We thus decided to 
normalize  for  each  sample  the  level of  26-HC and other 




decrease  in  the concentration of 26-HC.  Interestingly,  in 
an earlier study, Wuolikainen et al. (30) found that “total” 
26-HC in male ALS patients was similarly reduced. In com-
bination, these results suggest reduced transcription, trans-
lation,  or  activity  of  cholesterol  (25R)26-hydroxylase  in 
ALS.
Analysis of sterols, oxysterols, and cholestenoic and 
cholenoic acids in CSF
As  with  serum,  levels  of  cholesterol,  7-DHC  (plus 
8-DHC),  and  desmosterol  were  measured  in  CSF  from 
ALS patients (n = 20; 15 male, 5 female, mean age 61) and 
controls  (n = 15; 12 male, 3  female, mean age 75). The 




are as described in the Fig. 1 legend. Data for other sterols can be 
found in supplemental Table S3. Univariate t tests were performed 
against the control group. * P < 0.05; ** P < 0.01.
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dione; 7-hydroxy-26-norcholest-4-ene-3,24-dione (7H,26-
nor-C-3,24-diO); and the -oxidation product 7-hydroxy-
3-oxochol-4-en-24-oic acid (7H,3O-4-BA).  With  the 
exception of the latter compound, all of the peroxisomal 




is  conversion  to  24S-HC  via  the  neuron-specific  enzyme 
CYP46A1 (32, 33), accounting for approximately two-thirds 




fied and nonesterified sterol. In most studies, concentra-
tions of total cholesterol or of total hydroxycholesterols are 
be explained because CYP7A1 is not expressed in the CNS, 
being  liver-specific (Fig. 3) (25). The  level of 26-HC was 
not  significantly  lower  in CSF from ALS patients (0.09 ± 
0.06 ng/µg cholesterol)  compared with controls  (0.13 ± 
0.07 ng/µg cholesterol), but  its downstream metabolites 
3-HCA  (P  <  0.01),  3,7-dihydroxycholest-5-en-26-oic 
acid (3,7-diHCA;  P  <  0.05),  and  7-hydroxy-3-
oxocholest-4-en-26-oic  acid  (7H,3O-CA; P  <  0.01)  were 
all reduced in concentration (ng/µg cholesterol) in ALS 
CSF (Fig. 6). Whereas (25R)26-carboxylation by CYP27A1 
occurs in the mitochondria, 7-hydroxylation by CYP7B1, 
the oxysterol 7-hydroxylase, and oxidation of the 3-
hydroxy group by hydroxysteroid dehydrogenase  (HSD) 
3B7 occur in the endoplasmic reticulum, further metabo-
lism  to  bile  acids  proceeds  in  the  peroxisome  (31).  








t tests were performed against the control group. * P < 0.05; ** P < 0.01.
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(38, 39). Importantly, LXR is involved in control of lipo-
genesis and cholesterol homeostasis, and these mice 
showed increased cholesterol levels in spinal cord, gliosis, 
and inflammation preceding motor neuron loss and clini-
cal disease onset (40). In the present study, a loss of LXR 
signaling may result from reduced CNS levels of oxysterol 
and  cholestenoic  acid LXR-ligands,  ultimately  leading  to 
motor neuron pathology.
Although cholesterol cannot cross the blood-brain bar-
rier and be imported to, or exported from, the brain, 24S-




is exported from the brain to circulation. Further studies 
by Iuliano et al. (44) have shown that a precursor of this 
measured where sterols esterified with fatty acids are hy-
drolyzed and the total sterol is assayed, although it is the 
nonesterified sterols that are biologically active. Usually the 
ratio of esterified to nonesterified sterol in plasma is ap-
proximately 10:1 (36). Surprisingly, levels of total 24S-HC 









being particularly expressed in brain, and, interestingly, 
LXR/ mice show adult-onset motor neuron pathology 




Univariate t tests were performed against the control group. * P < 0.05; ** P < 0.01.











Supplemental Material can be found at:
276 Journal of Lipid Research Volume 58, 2017
cytokines and therefore development of neuroinflamma-
tion (40).
Importantly, the oxysterol 24S-HC and the cholestenoic 




quently,  LXR  signaling.  In  fact,  3,7-diHCA  has  been 
ascribed a neuroprotective role toward developing motor 
neurons through the LXRs, although the other two acids 





reduced  concentration  in  the  CSF.  Other  LXR  ligands 
found in the CSF, including 3-HCA,  3,7-diHCA,  and 
3,7-diHCA,  are  derived  from  cholesterol  in  astrocytes 
(49). The first enzyme in their synthesis from cholesterol is 
mitochondrial  CYP27A1  (Fig.  3).  Interestingly, CYP27A1 
has been identified as a susceptibility gene for sporadic 
ALS  (13).  Mutations  in  CYP27A1 leading to a defective 
CYP27A1 enzyme are the cause of the genetic neurodegen-
erative disorder cerebrotendinous xanthomatosis (50).
Further support for a role for oxysterols in neuroinflam-
mation comes from the recent report by Reboldi et al. link-
ing side-chain hydroxylated cholesterol molecules (i.e., 
25-HC)  to  inhibition of  Il1b transcription and inflamma-
some activity by antagonizing the sterol regulatory element-
binding protein-driven cholesterol biosynthesis pathway 
(51). Importantly, it has been shown that 24S-HC will also 
inhibit  SREBP-driven  cholesterol  biosynthesis  (52),  so, 
acid, 7,26-dihydroxycholest-4-en-3-one (7,26-diHCO), is 
also exported from the brain to circulation, as is its isomer 
7,25-diHCO. In another study, Ogundare et al. (45) have 
shown that multiple parts of the acidic pathway of bile acid 
biosynthesis are active in the CNS.
A key finding of the present study was the increase in 
concentration of nonesterified cholesterol in the CSF of 
ALS patients (Fig. 4). This  increase was associated with a 
decrease in the cholesterol-normalized concentration of 
brain-derived oxysterols and cholestenoic acids, but not of 
those cholesterol metabolites imported from the circula-
tion (Figs. 5 and 6). One explanation for increased choles-
terol  levels  in  CSF  of  ALS  patients  is  that  cholesterol  is 
released from membranes as neurons die, and metabolic 
pathways are saturated and insufficient to remove this ex-
cess in ALS patients (Fig. 7). An alternative explanation is 
that there is dysregulated transport of sterols between neu-
rons and glia, resulting in inefficient cholesterol metabo-
lism  in  the  CNS  of  ALS  patients  as  a  consequence  of 
ineffective  LXR  signaling.  This  latter  hypothesis  is  sup-
ported by studies on the LXR/ mouse, which not only 
shows adult motor neuron pathology, but also increased 
spinal cord cholesterol levels, accumulation of cholesterol 
in ventral horn neurons, gliosis, and inflammation preced-
ing motor neuron loss and clinical disease onset (40). How 
LXR protects against motor neuron loss is not exactly 
clear, but LXR is known to attenuate the inflammatory 
response  (46),  and  neuroinflammation  is  an  important 
pathogenic  factor  in ALS  (47).  In  fact,  proinflammatory 
cytokines and monocyte chemotactic protein 1 were in-
creased  in LXR/ mice,  suggesting  that  LXR plays a 
fundamental role in the CNS by reducing levels of 
Fig. 7.  Hypothetical model of cholesterol homeosta-
sis in neurons and astrocytes. Neurons import choles-
terol from astrocytes mediated by apolipoprotein 
(APO) E (green circle) (53). Neurons dispose of cho-
lesterol  by  ATP-binding  cassette  (ABC)  transporters 
(blue circle) and APOA1 (red circle), by  the  forma-
tion of 24S-HC, or via return to astrocytes via an un-
known  mechanism  (broken  arrow).  Activation  of 
LXR by oxysterols or cholestenoic acids leads to in-
creased expression of ABC transporters and increased 
sterol release. Impaired metabolism of cholesterol in 
astrocytes as suggested in the present study of ALS pa-
tients may result in a greater flux of cholesterol out of 
astrocytes into the CSF and also into neurons. A reduc-
tion of metabolism of cholesterol to cholestenoic acids 
will result in a decrease in LXR ligands in astrocytes 
and lower amounts transported to neurons (broken 
arrow depicts unknown mechanism). A consequence 
will be increased cellular levels of cholesterol in 
neurons and reduced antiinflammatory signaling by 
LXR.











Supplemental Material can be found at:
Defective cholesterol metabolism in ALS 277
conversely,  reduced  levels  of  24S-HC  in  the CNS,  as  ob-
served in ALS, should result in enhanced cholesterol bio-
synthesis and Il1b transcription, inflammasome activity, 
and neuroinflammation.
In summary, we have identified elevated cholesterol con-
centrations in the CSF of ALS patients. When normalized 
to cholesterol, concentrations of glial-derived acidic me-
tabolites are reduced, but cholesterol metabolites imported 
from the circulation are not. These data point to impaired 
activity of the CYP27A1 enzyme leading to a failure of the 
CNS to remove excess cholesterol, which may be toxic to 
neuronal cells, compounded by a reduction in neuropro-
tective 3,7-diHCA and other LXR ligands (Fig. 7).
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